Orion Pharma Limited

ORIONPHARM

BD0486OPL004

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
72.9 ^BDT	-2.93%		-3.19%	-8.42%

04-30	Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
02-04	Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI

Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2018

November 01, 2018 at 11:05 am

The board of directors of Orion Pharma Limited has recommended 15% cash dividend for the year ended on June 30, 2018.

Latest news about Orion Pharma Limited

Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	04-29	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-04	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	11-15	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	02/05/23	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	12/02/23	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	19/11/22	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended June 30, 2022	14/11/22	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	26/04/22	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	29/01/22	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2021	14/11/21	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter Ended December 31, 2020	01/02/21	CI
Orion Pharma Limited Recommends Cash Divided for the Year Ended on June 30, 2020	09/11/20	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter Ended March 31, 2020	19/05/20	CI
Orion Pharma Limited Appoints Zareen Karim as Managing Director	09/01/20	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2019	12/11/19	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2019	07/11/19	CI
Orion Pharma Limited Reports Earnings Results for the Third Quarter Ended March 31, 2019	06/05/19	CI
Orion Pharma Limited Reports Earnings Results for the Second Quarter Ended December 31, 2018	04/02/19	CI
Orion Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2018	14/11/18	CI
Orion Pharma Limited Recommends Cash Dividend for the Year Ended on June 30, 2018	01/11/18	CI
Orion Pharma Limited Reports Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended March 31, 2018	29/04/18	CI
Orion Pharma Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2017	29/01/18	CI
Orion Pharma Limited Announces Consolidated Unaudited Earnings Results for the First Quarter Ended September 30, 2017	14/11/17	CI
Orion Pharma Limited Reports Consolidated Earnings Results for the Year Ended on June 30, 2017	07/11/17	CI
Orion Pharma Limited Announces Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 2017	01/05/17	CI

Orion Pharma Limited is a Bangladesh-based pharmaceutical company. The Company is engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health- related consumer products. The Company's products include Ambronil, Angimet MR, Arovent, Axet, Avison, Azalid, Angimet, Alve, Anvert, Baclon, Betacal, Bisoloc, Bonec, Broket, Bromazep, Boncare, Sefin, Stimulin, Silvage, ROVEX, Rupenta, Rispa, Riz, Rivo, Procap, Pep Plus, Pep, Pedicon, Pedicef, Oranex Capsule, Orsal Syrup, Orsal, Ortac, Ormin, Orlev, Orioplex, Oriodox, Orfenac, Onium, Onasia, Oclazid, Novoxen, Novodol Tablet, Nidazyl, Nervex, NOVELTA, Nosedex, Noak, Newage, Neulyn, Nugesic, Losan-D, Losan D, Losan, Lopres, Lipex, GoldKid, Goldage, Glory, Ezylax Syrup, Eroflam, Exor, Eprel, ESP, Enliven, EC PLUS, EC, Deslor Plus, Deslor, Deconil, Cosy, Co-Axet, Cloramin Syrup, Cefditor, Conaz, Combivit, Clognil Plus, Clognil and CCB.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORION PHARMA LIMITED	-8.42%	146M
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+30.34%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	209B
ROCHE HOLDING AG	-6.83%	203B
AMGEN INC.	+7.09%	165B